Tocilizumab in hospitalized patients with COVID-19 pneumonia

IO Rosas, N Bräu, M Waters, R Go, BD Hunter… - MedRxiv, 2020 - medrxiv.org
ABSTRACT BACKGROUND COVID-19 is associated with immune dysregulation and
hyperinflammation. Tocilizumab is an anti–interleukin-6 receptor antibody. METHODS …
被引用次数：131 相关文章
[HTML] europepmc.org

[HTML][HTML] Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia

IO Rosas, N Bräu, M Waters, R Go, BD Hunter… - 2020 - europepmc.org
BACKGROUND COVID-19 is associated with immune dysregulation and hyperinflammation.
Tocilizumab is an anti–interleukin-6 receptor antibody. METHODS Patients hospitalized with …
[PDF] archive.org

[PDF][PDF] Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia

IO Rosas, N Bräu, R Go, S Bhagani, D Skiest, S Mariam… - scholar.archive.org
Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia Ivan O. Rosas, MD, Norbert
Bräu, MD, MBA, Michael Waters, M Page 1 1 Tocilizumab in Hospitalized Patients With …

Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia

I Rosas, N Bräu, M Waters, RC Go, BD Hunter… - 2020 - pesquisa.bvsalud.org
Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia | PREPRINT-MEDRXIV
loading 1 2 3 +A A -A 3.Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia This …

Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia

I Rosas, N Bräu, M Waters, RC Go, BD Hunter… - 2020 - pesquisa.bvsalud.org
ABSTRACT BACKGROUNDCOVID-19 is associated with immune dysregulation and
hyperinflammation. Tocilizumab is an anti-interleukin-6 receptor antibody …